9 METERS BIOPHARMA INC (NMTR) Stock Price & Overview
NASDAQ:NMTR • US6544052086
The current stock price of NMTR is 0.0722 USD. Today NMTR is down by -42.97%. In the past month the price decreased by -88.9%. In the past year, price decreased by -98.36%.
NMTR Key Statistics
- Market Cap
- 1.035M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.46
- Dividend Yield
- N/A
NMTR Stock Performance
NMTR Stock Chart
NMTR Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to NMTR. When comparing the yearly performance of all stocks, NMTR is a bad performer in the overall market: 99.89% of all stocks are doing better.
NMTR Earnings
NMTR Forecast & Estimates
11 analysts have analysed NMTR and the average price target is 10.58 USD. This implies a price increase of 14557.2% is expected in the next year compared to the current price of 0.0722.
NMTR Groups
Sector & Classification
NMTR Financial Highlights
Over the last trailing twelve months NMTR reported a non-GAAP Earnings per Share(EPS) of -3.46. The EPS decreased by -8.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NMTR Ownership
NMTR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 28.77 | 951.275B | ||
| JNJ | JOHNSON & JOHNSON | 21.01 | 584.618B | ||
| MRK | MERCK & CO. INC. | 22.88 | 289.542B | ||
| PFE | PFIZER INC | 9.09 | 152.449B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.6 | 123.471B | ||
| ZTS | ZOETIS INC | 17.29 | 51.652B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.95 | 26.443B | ||
| VTRS | VIATRIS INC | 5.75 | 16.373B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.82 | 11.902B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.414B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.72B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.704B | ||
| AMRX | AMNEAL PHARMACEUTICALS INC | 13.87 | 4.169B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NMTR
Company Profile
9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on unmet needs in gastroenterology. The company is headquartered in Raleigh, North Carolina and currently employs 10 full-time employees. The company went IPO on 2016-07-08. The firm is engaged in developing novel treatments for people with rare digestive diseases, gastrointestinal (GI) conditions with unmet needs, and debilitating disorders in which the biology of the gut is a contributing factor. The firm is developing vurolenatide, a proprietary long-acting GLP-1 agonist in Phase 3 development for short bowel syndrome as well as near clinical-stage assets including NM-136 for obesity disorders. The long-acting linker technology is designed specifically to address the gastric effects in SBS patients by slowing digestive transit time. Vurolenatide uses proprietary XTEN technology to extend the half-life of exenatide, potentially allowing for every other week dosing (Q2W). NM-136 is a long-acting, highly specific, humanized anti-GIP monoclonal antibody.
Company Info
IPO: 2016-07-08
9 METERS BIOPHARMA INC
4509 Creedmoor Road, Suite 600
Raleigh NORTH CAROLINA 27615 US
CEO: John Temperato
Employees: 10
Phone: 19192751933.0
9 METERS BIOPHARMA INC / NMTR FAQ
What does 9 METERS BIOPHARMA INC do?
9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on unmet needs in gastroenterology. The company is headquartered in Raleigh, North Carolina and currently employs 10 full-time employees. The company went IPO on 2016-07-08. The firm is engaged in developing novel treatments for people with rare digestive diseases, gastrointestinal (GI) conditions with unmet needs, and debilitating disorders in which the biology of the gut is a contributing factor. The firm is developing vurolenatide, a proprietary long-acting GLP-1 agonist in Phase 3 development for short bowel syndrome as well as near clinical-stage assets including NM-136 for obesity disorders. The long-acting linker technology is designed specifically to address the gastric effects in SBS patients by slowing digestive transit time. Vurolenatide uses proprietary XTEN technology to extend the half-life of exenatide, potentially allowing for every other week dosing (Q2W). NM-136 is a long-acting, highly specific, humanized anti-GIP monoclonal antibody.
What is the stock price of 9 METERS BIOPHARMA INC today?
The current stock price of NMTR is 0.0722 USD. The price decreased by -42.97% in the last trading session.
What is the dividend status of 9 METERS BIOPHARMA INC?
NMTR does not pay a dividend.
How is the ChartMill rating for 9 METERS BIOPHARMA INC?
NMTR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Can you provide the PE ratio for NMTR stock?
9 METERS BIOPHARMA INC (NMTR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.46).
When does 9 METERS BIOPHARMA INC (NMTR) report earnings?
9 METERS BIOPHARMA INC (NMTR) will report earnings on 2023-08-14, before the market open.